Emicizumab prophylaxis and health-related outcomes in persons with hemophilia a (PwHA) with inhibitors: HAVEN 1 study

被引：0
|
作者：
Oldenburg, J. [1 ]
Mahlangu, J. N. [2 ,3 ]
Bujan, W. [4 ]
Trask, P. C. [5 ]
von Mackensen, S. [6 ]
Callaghan, M. U. [7 ]
Young, G. [8 ]
Asikanius, E. [9 ]
Peyvandi, F. [10 ]
Santagostino, E. [10 ]
Kruse-Jarres, R. [11 ]
Negrier, C. [12 ]
Kessler, C. [13 ]
Levy, G. G. [14 ]
Windyga, J. [15 ]
Shima, M. [16 ]
机构：
[1] Univ Klinikum Bonn, Bonn, Germany
[2] Univ Witwatersrand, Fac Hlth Sci, Haemophilia Comprehens Care Ctr, Johannesburg, South Africa
[3] NHLS, Johannesburg, South Africa
[4] Inst Costarricense Invest Cient, San Jose, Costa Rica
[5] Genentech Inc, San Francisco, CA 94080 USA
[6] Univ Med Ctr Hambur Eppendorf, Dept Med Psychol, Hamburg, Germany
[7] Childrens Hosp Michigan, Detroit Med Ctr, Detroit, MI 48201 USA
[8] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA USA
[9] F Hoffmann La Roche Ltd, Basel, Switzerland
[10] Osped Maggiore Policlin, IRCCS Ca Granda Fdn, Milan, Italy
[11] Univ Washington, Washington Ctr Bleeding Disorders BloodWorks NW, Seattle, WA 98195 USA
[12] Univ Claude Bernard, Louis Pradel Cardiol Hosp, Lyon, France
[13] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[14] Genentech Inc, Pharma Dev Oncol, San Francisco, CA 94080 USA
[15] Inst Hematol & Transfus Med, Warsaw, Poland
[16] Nara Med Univ, Dept Pediat, Kashihara, Nara, Japan
来源：
HAEMOPHILIA | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P120
引用
收藏
页码：89 / 90
页数：2
相关论文
共 50 条
  • [31] Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies
    Mahlangu, Johnny
    Jimenez-Yuste, Victor
    Ventriglia, Giuliana
    Niggli, Markus
    Barlera, Simona
    Hermans, Cedric
    Lehle, Michaela
    Chowdary, Pratima
    Jew, Lyle
    Windyga, Jerzy
    Frenzel, Laurent
    Schmitt, Christophe
    Castaman, Giancarlo
    Pipe, Steven W.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (02)
  • [32] Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study
    Mancuso, Maria Elisa
    Mahlangu, Johnny
    Sidonio, Robert, Jr.
    Trask, Peter
    Uguen, Marianne
    Chang, Tiffany
    Shima, Midori
    Young, Guy
    Oldenburg, Johannes
    von Mackensen, Sylvia
    HAEMOPHILIA, 2020, 26 (06) : 1009 - 1018
  • [33] Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
    Fredrik Jonsson
    Christophe Schmitt
    Claire Petry
    Francois Mercier
    Nicolas Frey
    Sylvie Retout
    Clinical Pharmacokinetics, 2021, 60 : 931 - 941
  • [34] Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study
    Kiialainen, Anna
    Niggli, Markus
    Kempton, Christine L.
    Castaman, Giancarlo
    Chang, Tiffany
    Paz-Priel, Ido
    Adamkewicz, Joanne, I
    Levy, Gallia G.
    HAEMOPHILIA, 2022, 28 (06) : 1033 - 1043
  • [35] Emicizumab Prophylaxis in Persons with Hemophilia A, Aged ≥50 Years, with Comorbidities - Pooled Data from Four Phase III Studies (HAVEN 1, 3, and 4, and STASEY)
    Jimenez-Yuste, Victor
    Oldenburg, Johannes
    Tzeng, Eunice
    Trzaskoma, Ben
    Sanabria, Fabian
    Mahlangu, Johnny
    BLOOD, 2021, 138
  • [36] Health-related quality of life of patients with hemophilia and inhibitors
    Lee, W. C.
    Brown, M.
    Joshi, A., V
    Foster, T.
    Pashos, C. L.
    VALUE IN HEALTH, 2008, 11 (03) : A164 - A164
  • [37] Factor VIII use in the treatment of breakthrough bleeds in persons with haemophilia a without inhibitors on emicizumab prophylaxis: the phase III HAVEN 3 study experience
    Callaghan, M.
    Trzaskoma, B.
    Ko, R.
    Lee, L.
    Patel, A.
    Tzeng, E.
    Shah, M.
    Chang, T.
    Niggli, M.
    Dhalluin, C.
    Paz-Priel, I.
    Mahlangu, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 44 - 45
  • [38] Health-related quality of life in patients with hemophilia and inhibitors
    Lee, W.
    Brown, M.
    Joshi, A.
    Pashos, C.
    HAEMOPHILIA, 2008, 14 : 47 - 47
  • [39] Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)
    Callaghan, Michael U.
    Negrier, Claude
    Paz-Priel, Ido
    Chang, Tiffany
    Chebon, Sammy
    Lehle, Michaela
    Mahlangu, Johnny
    Young, Guy
    Kruse-Jarres, Rebecca
    Mancuso, Maria Elisa
    Niggli, Markus
    Kuebler, Peter
    Bienz, Nives Selak
    Shima, Midori
    Jimenez-Yuste, Victor
    Schmitt, Christophe
    Asikanius, Elina
    Levy, Gallia
    Pipe, Steven W.
    Oldenburg, Johannes
    BLOOD, 2020, 136
  • [40] Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors
    Castaman, Giancarlo
    Peyvandi, Flora
    Hovinga, Johanna A. Kremer
    Schutgens, Roger E. G.
    Robson, Susan
    Moreno, Katya
    Jimenez-Yuste, Victor
    TH OPEN, 2024, 08 (01) : e42 - e54
12345